The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.
Sotrovimab is agreed as RED for prescription only by the commissioned CMDU service (not for prescribing through A&E / hospital clinics)
*if a patient who falls into one of the highest risk cohorts is in hospital and gets COVID-19 (not admitted due to COVID) then these individuals should be treated with Paxlovid / Sotrovimab in line with NICE TA878 whilst they are an inpatient.
Patients eligible for sotrovimab will be able to obtain a supply from the locally designated Community Pharmacy commissioned to provide this service. The Patient Specific Direction (PSD) will be sent directly to the commissioned pharmacy from the CMDU. The infusion will be given in the patient’s place of residence by the commissioned IV administration service.
The commissioned pharmacy details can be found in the document "CMDU Community Pharmacies" (updated June 2025)
The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.
Sotrovimab is agreed as RED for prescription only by the commissioned CMDU service (not for prescribing through A&E / hospital clinics)
*if a patient who falls into one of the high risk cohorts is in hospital and gets COVID-19 (not admitted due to COVID) then these individuals should be treated with Paxlovid / Sotrovimab in line with NICE TA878 whilst they are an inpatient.
